Although its increased expression was shown to negatively regulate tumor MHC I surface expression and promote STAT3 oncogene activation leading to tumor malignancy [45,46], calnexin expression levels were significantly higher only in Stage I lung cancer patients when compared to healthy controls, while in colorectal cancer (CRC), no associations were found between higher expressions of calnexin in CRC Stages II or III compared to normal tissue samples [47,48]. The gene discussed is CANX; the disease is neoplasm.